Skip to main content

Architecture doctrine

One configurable product, designed around evidence and authority

The PHARMORIS architecture must preserve tenant boundaries, source provenance, human authority and repeatable configuration before any buyer readiness claim can progress.

Discuss architecture and assuranceReview the security boundary
Product model | One configurable productArchitecture standard | Server derived authorityReadiness | Evidence dependent

Required layers

Separate source handling, governance and operating state.

The intended architecture keeps source specific ingestion separate from shared workflow logic and tenant specific configuration.

A registry entry or receipt is not proof that an operational adapter exists.

01

Source layer

Record provenance, rights, receipt status and source specific transformation.

Required doctrine
02

Governance layer

Apply authorised roles, decision gates and review requirements.

Required doctrine
03

Operating layer

Maintain ActionCase state, ownership, blockers and closure.

Required doctrine

Authority boundary

Tenant and role authority must not be trusted from the client.

Buyer readiness requires tenant isolation and role authority to be derived and enforced by the server. Synthetic or bypassable authentication is a no go condition.

Local adopter responsibilities must remain distinct from supplier responsibilities.

Human decision requiredProceed only inside an evidenced and governed scope.
01

Tenant context

Derive tenant scope from trusted server side identity and policy.

02

Role authority

Enforce permissions on the server for every protected action.

03

Audit context

Retain the actor, source, decision and exact product version needed for review.

Re architecture triggers

Change the design before unsafe assumptions become product debt.

The route must be reconsidered when tenant isolation is unsafe, integrations fail, source rights are insufficient or local assurance materially alters the design.

Human decision requiredProceed only inside an evidenced and governed scope.
01

Security

Re architect when tenant or role separation cannot be evidenced.

02

Source rights

Stop or redesign when the intended use of data is not authorised.

03

Software economics

Narrow or redesign when customer forks or operating costs destroy repeatability.

Classified public record

Inspect related publisher records

MEDICINES ANALYSIS + EXECUTION

You can identify the opportunity and still lose it in delivery.

Explore the financial, operational and governance questions that shaped PHARMORIS. Then check the product’s dated status before treating the model as implemented.

  1. PharmaphorumContributed analysis

    Approval is not access: Pilots' real test is implementation

    In pharmaphorum, Varun Sharma argues that medicines access pilots should measure the full chain from recommendation to funded delivery and outcomes.

    Read the implementation argument
  2. AI Ethics Now / University of Warwick IATLPodcast appearance

    AI and Accountability: When Does a Suggestion Become a Decision?

    Varun Sharma joins AI Ethics Now to examine false confidence, human responsibility and the point where AI assisted suggestions become accountable decisions.

    Hear the human accountability discussion
  3. NEUVIOR Founder ReflectionsNEUVIOR analysis

    After NICE: making medicines access operational

    A recommendation can clarify what should be available. You still need an accountable route from evidence to a local decision, delivery and review.

    Map the work after a medicines recommendation
Explore every medicines analysis

NEUVIOR Insights and After Publication reflections are company or founder analysis. Publisher records evidence publication, not endorsement, adoption, product readiness, savings or clinical outcomes.

Make the next step useful

Bring the problem that needs a clearer decision.

Tell us what is stuck, what decision you need to make and what a better outcome would change. We will connect you to the most relevant NEUVIOR, PHARMORIS, media or investor route.

Discuss architecture and assuranceSpeak with NEUVIOR

QUESTIONS · ANSWERED DIRECTLY

The useful answers, in one place.

Browse every question
01What problem does PHARMORIS address?

Medicines teams can identify an opportunity yet still lack a consistent way to connect the evidence to a decision, accountable owner, delivery tasks, blockers and a reviewed result. PHARMORIS is being built for that operational gap.

02Who is PHARMORIS intended for?

PHARMORIS is intended for authorised medicines, pharmacy, finance, procurement and operational teams working inside responsible healthcare institutions. Scope and deployment requirements must be agreed for each organisation.

03Does PHARMORIS replace professional judgement?

No. PHARMORIS is designed to structure evidence and accountable work while keeping professional and institutional decisions with authorised people.

04What is an ActionCase?

An ActionCase is the governed unit of work at the centre of PHARMORIS. It can hold the evidence basis, scope, owner, decisions, tasks, blockers and review record for a medicine opportunity.

05Is PHARMORIS ready for production or deployed?

PHARMORIS is under controlled development and should not be interpreted as a live, adopted or clinically approved product unless a current, specific deployment record says otherwise.

06Does the public demonstration use patient data?

No. Public and representative demonstrations are designed without live data that identifies patients. Any future institutional data scope would require separate governance, security and contractual controls.